By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Biotechnology have been published. According to news originating from Durban, South Africa, by NewsRx correspondents, research stated, "Gene transfer using non-viral vectors is a promising approach for the safe delivery of nucleic acid therapeutics. In this study, we investigate a lipid-based system for targeted gene delivery to malignant cells overexpressing the folate receptor (FR)."
Our news journalists obtained a quote from the research from the University of KwaZulu-Natal, "Cationic liposomes were formulated with and without the targeting ligand folate conjugated to distearoylphosphatidyl ethanolamine polyethylene glycol 2000 (DSPE-PEG(2000)), the novel cytofectin 3 beta[N(N-1,N-1-dimethlaminopropylsuccinamidoethane)-carbamoyl]cholesterol (SG04), which contains a 13 atom, 15 angstrom spacer element, and the helper lipid, dioleoylphosphatidylethanolamine (DOPE). Physicochemical parameters of the liposomes and lipoplexes were obtained by zeta sizing, zeta potential measurement and cryo-TEM. DNA-binding and protection capabilities of liposomes were confirmed by gel retardation assays, EtBr intercalation and nuclease protection assays. The complexes were assessed in an in vitro system for their effect on cell viability using the MIT assay, and gene transfection activity using the luciferase assay in three cell lines; HEK293 (FR-negative), HeLa (FR+-positive), KB (FR++-positive). Low cytotoxicities were observed in all cell lines, while transgene activity promoted by folate-tagged lipoplexes in FR-positive lines was tenfold greater than that by untargeted constructs and cell entry by folate complexes was demonstrably by FR mediation."
According to the news editors, the research concluded: "These liposome formulations have the design capacity for in vivo application and may therefore be promising candidates for further development."
For more information on this research see: Novel serum-tolerant lipoplexes target the folate receptor efficiently. European Journal of Pharmaceutical Sciences, 2014;59():83-93. European Journal of Pharmaceutical Sciences can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutical Sciences - www.elsevier.com/wps/product/cws_home/523997)
The news correspondents report that additional information may be obtained from S. Gorle, University of KwaZulu Natal, Discipline Biochem, Nonviral Gene Delivery Lab, ZA-4000 Durban, South Africa. Additional authors for this research include M. Ariatti and M. Singh (see also Biotechnology).
Keywords for this news article include: Biotechnology, Durban, Therapy, Liposomes, South Africa, Drug Delivery Systems
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC